BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

334 related articles for article (PubMed ID: 28417853)

  • 1. The Role of
    Harrison DJ; Parisi MT; Shulkin BL
    Semin Nucl Med; 2017 May; 47(3):229-241. PubMed ID: 28417853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PET with
    Harrison DJ; Parisi MT; Khalatbari H; Shulkin BL
    PET Clin; 2020 Jul; 15(3):333-347. PubMed ID: 32498989
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The impact of
    Elmanzalawy A; Vali R; Chavhan GB; Gupta AA; Omarkhail Y; Amirabadi A; Shammas A
    Pediatr Radiol; 2020 Feb; 50(2):252-260. PubMed ID: 31628508
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [
    Metser U; Kulanthaivelu R; Salawu A; Razak A; Mak V; Li X; Langer DL; MacCrostie P; Singnurkar A
    J Nucl Med; 2023 Sep; 64(9):1371-1377. PubMed ID: 37414444
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Utility of positron emission tomography/computed tomography (PET/CT) imaging in the evaluation of sarcomas: A systematic review.
    Lim HJ; Johnny Ong CA; Tan JW; Ching Teo MC
    Crit Rev Oncol Hematol; 2019 Nov; 143():1-13. PubMed ID: 31449981
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Role of
    Mercolini F; Zucchetta P; Jehanno N; Corradini N; Van Rijn RR; Rogers T; Cameron A; Scarzello G; Coppadoro B; Minard-Colin V; Gallego S; Chisholm J; Merks JH; Bisogno G
    Eur J Cancer; 2021 Sep; 155():155-162. PubMed ID: 34385068
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 18F-fluorodeoxyglucose uptake of bone and soft tissue sarcomas in pediatric patients.
    Walter F; Federman N; Apichairuk W; Nelson S; Phelps ME; Allen-Auerbach M; Walter MA; Czernin J
    Pediatr Hematol Oncol; 2011 Oct; 28(7):579-87. PubMed ID: 21936620
    [TBL] [Abstract][Full Text] [Related]  

  • 8.
    Bosma SE; Vriens D; Gelderblom H; van de Sande MAJ; Dijkstra PDS; Bloem JL
    Skeletal Radiol; 2019 Nov; 48(11):1735-1746. PubMed ID: 31016339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pretreatment tumor SUV
    Ha SC; Oh JS; Roh JL; Moon H; Kim JS; Cho KJ; Choi SH; Nam SY; Kim SY
    Eur J Nucl Med Mol Imaging; 2017 Jan; 44(1):33-40. PubMed ID: 27448574
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatric bone sarcoma: diagnostic performance of ¹⁸F-FDG PET/CT versus conventional imaging for initial staging and follow-up.
    Quartuccio N; Fox J; Kuk D; Wexler LH; Baldari S; Cistaro A; Schöder H
    AJR Am J Roentgenol; 2015 Jan; 204(1):153-60. PubMed ID: 25539251
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
    Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
    Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Advantages of
    Németh Z; Boér K; Borbély K
    Pathol Oncol Res; 2019 Jan; 25(1):131-136. PubMed ID: 28994004
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Post-treatment FDG PET/CT predicts progression-free survival in young patients with small round blue cell tumors: Ewing sarcoma and PNET.
    Sobic Saranovic DP; Nikitovic M; Saponjski J; Grozdic Milojevic I; Paripovic L; Saranovic D; Beatovic S; Artiko VM
    Eur J Radiol; 2020 Aug; 129():109076. PubMed ID: 32446127
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of (18) F-FDG-PET-CT and Bone Scintigraphy for Evaluation of Osseous Metastases in Newly Diagnosed and Recurrent Osteosarcoma.
    Hurley C; McCarville MB; Shulkin BL; Mao S; Wu J; Navid F; Daw NC; Pappo AS; Bishop MW
    Pediatr Blood Cancer; 2016 Aug; 63(8):1381-6. PubMed ID: 27082077
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography for staging of pediatric sarcoma patients: results of a prospective multicenter trial.
    Völker T; Denecke T; Steffen I; Misch D; Schönberger S; Plotkin M; Ruf J; Furth C; Stöver B; Hautzel H; Henze G; Amthauer H
    J Clin Oncol; 2007 Dec; 25(34):5435-41. PubMed ID: 18048826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Molecular imaging of sarcomas with FDG PET.
    Mendoza H; Nosov A; Pandit-Taskar N
    Skeletal Radiol; 2023 Mar; 52(3):461-475. PubMed ID: 36173459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diffusion-weighted MRI and 18F-FDG-PET/CT imaging: competition or synergy as diagnostic methods to manage sarcoma of the uterus? A systematic review of the literature.
    Dubreuil J; Tordo J; Rubello D; Giammarile F; Skanjeti A
    Nucl Med Commun; 2017 Jan; 38(1):84-90. PubMed ID: 27898647
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is there a need for dedicated bone imaging in addition to 18F-FDG PET/CT imaging in pediatric sarcoma patients?
    Walter F; Czernin J; Hall T; Allen-Auerbach M; Walter MA; Dunkelmann S; Federman N
    J Pediatr Hematol Oncol; 2012 Mar; 34(2):131-6. PubMed ID: 22134608
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual-time point 18FDG-PET/CT imaging may be useful in assessing local recurrent disease in high grade bone and soft tissue sarcoma.
    Dancheva Z; Bochev P; Chaushev B; Yordanova T; Klisarova A
    Nucl Med Rev Cent East Eur; 2016; 19(1):22-7. PubMed ID: 26841376
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Functional image in soft tissue sarcomas: An update of the indications of
    Rodríguez-Alfonso B; Simó-Perdigó M; Orcajo Rincón J
    Rev Esp Med Nucl Imagen Mol (Engl Ed); 2020; 39(4):233-243. PubMed ID: 32616457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.